Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104867365
CMS profile
321938
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,820.00

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $1,750.00 1
Food and Beverage $70.00 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $1,750.00 1
Merck Sharp & Dohme LLC $70.00 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J GEORGE

NPI 1104867365 · CMS profile ID 321938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1104867365?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $1,820.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $35.0009/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141839417 CMS
Merck Sharp & Dohme LLC $35.0004/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141713026 CMS
PFIZER INC. $1,750.0003/06/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131470386 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,139.61 16
PY2020 $806.00 2
PY2021 $5,850.00 2
PY2022 $5,602.52 7
PY2023 $299.42 5
PY2024 $1,820.00 3
PY2025 $2,260.64 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,584.60 83
PY2024 Recipient $2,598.05 11
PY2024 Principal investigator $596,039.96 28
PY2023 Principal investigator $1,130,234.11 90
PY2022 Principal investigator $1,675,365.46 75
PY2021 Principal investigator $2,129,940.43 124
PY2020 Principal investigator $2,169,106.03 143
PY2019 Principal investigator $2,064,075.98 203

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

83 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $21,901.65 12/31/2025 Non-covered Recipient Entity
University of Florida College of Medicine
A Phase 1,2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers No dispute reported 06/30/2026 1232932884
Principal investigator 1 Merck Sharp & Dohme LLC $10,631.45 12/31/2025 Non-covered Recipient Entity
University of Florida College of Medicine
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 1232935085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $34,827.00 12/18/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy No dispute reported 06/30/2026 1184277754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,547.70 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $358.80 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274302
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,686.80 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274304
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274306
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274308
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,275.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274310
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $538.20 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274312
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,081.30 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,404.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274318
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274320
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $910.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274322
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $179.40 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274324
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,833.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274326
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $358.80 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274328
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,027.10 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274330
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $600.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274332
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,966.70 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274334
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $538.20 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274338
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,968.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184274342
Principal investigator 1 PFIZER INC. $14,072.40 11/25/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228739258
Principal investigator 1 PFIZER INC. $2,015.00 11/24/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228728387
Principal investigator 1 Merck Sharp & Dohme LLC $16,859.50 11/19/2025 Non-covered Recipient Entity
University of Florida College of Medicine
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 1232935083
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261103
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,647.50 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $358.80 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,392.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $338.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,365.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261115
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $179.40 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $179.40 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261121
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $910.00 11/14/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184261123
Principal investigator 1 PFIZER INC. $2,600.00 11/11/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228729665
Principal investigator 1 Astellas Pharma Inc $1,470.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365683
Principal investigator 1 Astellas Pharma Inc $1,470.00 10/29/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365685
Principal investigator 1 PFIZER INC. $1,664.00 10/24/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228741210
Principal investigator 1 PFIZER INC. $6,890.00 10/24/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228741588
Principal investigator 1 Astellas Pharma Inc $2,717.00 10/08/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365687
Principal investigator 1 Astellas Pharma Inc $960.00 10/07/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365671
Principal investigator 1 Astellas Pharma Inc $1,470.00 10/07/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365673
Principal investigator 1 Astellas Pharma Inc $1,885.00 10/07/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365675
Principal investigator 1 Astellas Pharma Inc $15,284.00 10/07/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365677
Principal investigator 1 Organon Llc $2,500.00 09/24/2025 Non-covered Recipient Entity
UNIVOFFLORIDA
7339-007 No dispute reported 06/30/2026 1173042100
Principal investigator 1 Organon Llc $400.00 09/24/2025 Non-covered Recipient Entity
UNIVOFFLORIDA
7339-007 No dispute reported 06/30/2026 1173042160
Principal investigator 1 Astellas Pharma Inc $1,470.00 09/08/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365679
Principal investigator 1 Astellas Pharma Inc $1,470.00 09/08/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365681
Principal investigator 1 PFIZER INC. $4,754.10 08/25/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228720383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,377.50 08/07/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184226483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,172.00 08/07/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184226485
Principal investigator 1 PFIZER INC. $82,356.70 08/04/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1 STUDY OF SGNSTNV IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228770206
Principal investigator 1 PFIZER INC. $260.00 07/28/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228786345
Principal investigator 1 PFIZER INC. $728.00 07/21/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228720415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,640.00 07/03/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184212627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $717.60 07/03/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184212629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 07/03/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184212631
Principal investigator 1 Astellas Pharma Inc $5,590.00 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365665
Principal investigator 1 Astellas Pharma Inc $4,469.40 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365667
Principal investigator 1 Astellas Pharma Inc $29,850.00 06/26/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation No dispute reported 06/30/2026 1225365669
Principal investigator 1 PFIZER INC. $260.00 06/16/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228777980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $65.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184206707
Principal investigator 1 AstraZeneca Pharmaceuticals LP $0.30 06/02/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
phase II single arm study of durvalumab and bevacizumab following transarterial radioembolization using yttrium 90 glass microspheres therasphere in unresectable hepatocellular carcinoma amenable to locoregional therapy No dispute reported 06/30/2026 1185548305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,047.70 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184197851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,064.20 05/22/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184197853
Principal investigator 1 PFIZER INC. $1,300.00 05/19/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228764851
Principal investigator 1 PFIZER INC. $1,872.00 05/05/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228762920
Principal investigator 1 PFIZER INC. $156.00 05/05/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228768433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,925.00 05/02/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,470.00 05/02/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,664.00 05/02/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,560.00 05/02/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1184192045
Principal investigator 1 PFIZER INC. $2,275.00 04/21/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228779642
Principal investigator 1 PFIZER INC. $416.00 04/21/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228781252
Principal investigator 1 Merck Sharp & Dohme LLC $12,420.00 04/16/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA 416
A phase 1b,2, multicenter, open-label study of S-531011 as monotherapy and in combination with an immune checkpoint inhibitor in participants with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1232935893
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $53,885.00 04/02/2025 Non-covered Recipient Entity
Uf Health Medical Oncology - Davis Cancer Pavilion
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers No dispute reported 06/30/2026 1235992779
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,683.00 03/12/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA BOARD OF TRUSTEES
Appendix F to the Precision Promise Master Protocol: Canakinumab and Spartalizumab in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Metastatic Pancreatic Cancer No dispute reported 06/30/2026 1190308144
Principal investigator 1 PFIZER INC. $104.00 02/03/2025 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS No dispute reported 06/30/2026 1228793783